Kymab, a Cambridge, UK-based biopharmaceutical company focused on human monoclonal antibodies, has entered into a cross-licensing and development agreement with EpimAb Biotherapeutics, a Shanghai, China-based biopharmaceutical company focused on bispecific antibodies, to develop bispecific therapeutic antibodies against multiple targets. The parties will focus on immuno-oncology and will combine EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to generate multiple bispecific antibodies combined with antibodies sourced from Kymab’s proprietary Kymouse platform.

Kymab will have the development and commercialization rights to these bispecifics in all geographical regions outside of China, and, under the agreement, EpimAb will have the rights for the China market. Each party is eligible to receive milestone payments and royalties for development programs pursued by the other party. This collaboration with Kymab represents EpimAb’s first license agreement outside of China.

EpimAb’s FIT-Ig technology is designed to generate bispecific antibodies with the resulting molecules fully retaining the biological properties of their parental monoclonal antibodies, according to EpimAb.

Source: EpimAb Biotherapeutics